Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin

HIV Clinical Trials

Volumn 11, Issue 1, 2010, Pages 1-10

  Rodriguez Torres, M ^a   Torriani, F ^b   Rockstroh, J ^c   Depamphilis, J ^d   Carosi, G ^e   Dieterich, D T ^f  

^a Department of Hematology and Oncology   (Puerto Rico)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d HOFFMANN LA ROCHE INC   (United States)

^e UNIVERSITY OF BRESCIA   (Italy)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

HIV HCV coinfection; On treatment response; Peginterferon; Predictors of response; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

EID: 77951266360     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1101-1     Document Type: Article

References (32)

1. Benhamou Y, Bochet M, Di MV, et al. Liver fi brosis progression in human immunodefi ciency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058. (Pubitemid 29458296)
2. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Effect of hepatitis C virus treatment in fi brosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodefi ciency virus: a paired liver biopsy study. J Hepatol. 2007;46:613-619. (Pubitemid 46402952)
3. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fi brosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21:2209-2216.
4. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779-789. (Pubitemid 40462940)
5. Salmon D, Robain M, Rockstroh JK, Benhamou Y. Therapeutic management of hepatitis and HIV infection in co-infected patients: results of a survey performed before the 2005 Consensus Conference. J Hepatol. 2006;44(Suppl. 1):S2-S5. (Pubitemid 43053864)
6. Bruno R, Sacchi P, Puoti M, et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defi c Syndr. 2007;46:297-303. (Pubitemid 350287356)
7. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodefi ciency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat. 2007;14:183-188. (Pubitemid 46257183)
8. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15:165-172. (Pubitemid 351143738)
9. Smit C, Van Den BC, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defi c Syndr. 2008;47:221-225. (Pubitemid 351172190)
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335-1374.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450. (Pubitemid 38988593)
12. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848. (Pubitemid 39628231)
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965. (Pubitemid 32913521)
14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
15. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
16. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 KD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708. (Pubitemid 38702672)
17. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004; 350:2265-2271. (Pubitemid 38669209)
18. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477. (Pubitemid 44142464)
19. Jacobson IM, Brown RS Jr, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46:982-990. (Pubitemid 350144762)
20. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257-267.
21. Thomas DL. Options for treatment of hepatitis C in HIVinfected persons. J Hepatol. 2006;44(1 Suppl):S40-S43. (Pubitemid 43053872)
22. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451-458.
23. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47:43-50. (Pubitemid 351171040)
24. Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol. 2007;47:580-587. (Pubitemid 47331763)
25. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/ HCV-coinfected individuals. HIV Med. 2006;7:248-254.
26. Martin-Carbonero L, Nunez M, Marino A, Alcocer F, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS. 2008;22:15-21. (Pubitemid 350294873)
27. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425-433. (Pubitemid 41111423)
28. Marcellin P, Jensen D, Hadziyannis S, Ferenci P. Differentiation of early virological response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (Pegasys) and ribavirin (Copegus) [abstract no. 1308]. Hepatology. 2007;46(4 Suppl. 1):818A.
29. Shea DO, Tuite H, Farrell G, et al. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. J Viral Hepat. 2008;15:482-489. (Pubitemid 351798985)
30. Payan C, Pivert A, Morand P, et al. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut. 2007;56:1111-1116. (Pubitemid 47123242)
31. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009 30;360:1839-1850.
32. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.